Cargando…
SHP-2 and PD-1-SHP-2 signaling regulate myeloid cell differentiation and antitumor responses
The inhibitory receptor PD-1 suppresses T cell activation by recruiting the phosphatase SHP-2. However, mice with a T-cell-specific deletion of SHP-2 do not have improved antitumor immunity. Here we showed that mice with conditional targeting of SHP-2 in myeloid cells, but not in T cells, had dimini...
Autores principales: | Christofides, Anthos, Katopodi, Xanthi-Lida, Cao, Carol, Karagkouni, Dimitra, Aliazis, Konstantinos, Yenyuwadee, Sasitorn, Aksoylar, Halil-Ibrahim, Pal, Rinku, Mahmoud, Mohamed A. A., Strauss, Laura, Tijaro-Ovalle, Natalia M., Boon, Louis, Asara, John, Vlachos, Ioannis S., Patsoukis, Nikolaos, Boussiotis, Vassiliki A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9810534/ https://www.ncbi.nlm.nih.gov/pubmed/36581713 http://dx.doi.org/10.1038/s41590-022-01385-x |
Ejemplares similares
-
Interaction of SHP-2 SH2 domains with PD-1 ITSM induces PD-1 dimerization and SHP-2 activation
por: Patsoukis, Nikolaos, et al.
Publicado: (2020) -
T Cell Metabolism in Cancer Immunotherapy
por: Aksoylar, Halil-Ibrahim, et al.
Publicado: (2020) -
Commentary on: Combination of Metabolic Intervention and T Cell Therapy Enhances Solid Tumor Immunotherapy
por: Christofides, Anthos, et al.
Publicado: (2021) -
Immune-related adverse effects of checkpoint immunotherapy and implications for the treatment of patients with cancer and autoimmune diseases
por: Ibis, Betul, et al.
Publicado: (2023) -
Targeting T Cell Metabolism for Improvement of Cancer Immunotherapy
por: Le Bourgeois, Thibault, et al.
Publicado: (2018)